SCHEMBL7007127

SCHEMBL7007127

Cc1c(C(=O)O)c2c(OCc3ccccc3)cccn2c1Cc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PLA2G1B P04054 14/20 0.66
PLA2G2A P14555 2/20 0.51
PLA2G10 O15496 1/20 0.51
PLA2G5 P39877 1/20 0.51
PLA2G2E Q9NZK7 1/20 0.51
ATP4A P20648 1/20 0.47
ATP4B P51164 1/20 0.47
FOLH1 Q04609 1/20 0.45
PTGER1 P34995 1/20 0.44
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
EDNRA P25101 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7102348 0.89 PLA2G1B (0.84) PLA2G1BPLA2G2APLA2G10PLA2G5PLA2G2E
SCHEMBL9083142 0.88 PLA2G1B (0.62) PLA2G1BPLA2G2APLA2G10PLA2G5PLA2G2E
SCHEMBL8322428 0.80 PLA2G1B (0.51) PLA2G1BPLA2G2APLA2G10PLA2G5PLA2G2E
SCHEMBL7018369 0.80 PLA2G1B (1.00) PLA2G1BPLA2G2APLA2G10PLA2G5PLA2G2E
SCHEMBL9082881 0.79 PLA2G1B (0.51) PLA2G1BPLA2G2APLA2G10PLA2G5PLA2G2E
SCHEMBL7006708 0.79 PLA2G1B (0.82) PLA2G1BPLA2G2APLA2G10PLA2G5PLA2G2E
SCHEMBL7017189 0.79 PLA2G1B (0.84) PLA2G1BPLA2G2APLA2G5PLA2G2E
SCHEMBL9080978 0.77 PLA2G1B (0.57) PLA2G1BATP4AATP4B
SCHEMBL7013779 0.76 PLA2G1B (0.83) PLA2G1BPLA2G2APLA2G10PLA2G5PLA2G2E
SCHEMBL7011013 0.76 PLA2G1B (0.84) PLA2G1BPLA2G2APLA2G5PLA2G2E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6645976-B1 Nonpancreatic secretory phospholipase (sPLA2) supressors such as 2-(3-Benzyl-8-hydroxy-2-ethylindolizin-1-yl)acetamide, administered to control release of fatty acid and prevent the arachidonic acid cascade; septic shock ELI LILLY AND COMPANY 2003-11-11 US disclosed
EP-0772596-B1 INDOLIZINE sPLA2 INHIBITORS LILLY CO ELI (US) 2003-10-01 EP disclosed
EP-0772596-A4 INDOLIZINE sPLA2 INHIBITORS LILLY CO ELI (US) 1999-01-13 EP disclosed
EP-0772596-A1 INDOLIZINE sPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 1997-05-14 EP disclosed
WO-1996003383-A1 INDOLIZINE sPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 1996-02-08 WO disclosed